<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="660">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152563</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-023</org_study_id>
    <nct_id>NCT05152563</nct_id>
  </id_info>
  <brief_title>A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis</brief_title>
  <acronym>ENIGMA-SC</acronym>
  <official_title>A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of Subcutaneous AK002 in Subjects With Moderate to Severe Eosinophilic Gastritis and/or Eosinophilic Duodenitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of subcutaneous&#xD;
      lirentelimab (AK002), given monthly for 6 doses, in subjects with moderate to severe&#xD;
      Eosinophilic Gastritis and/or Eosinophilic Duodenitis who have an inadequate response with,&#xD;
      lost response to, or were intolerant to standard therapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Responders as determined by gastric or duodenal tissue eosinophil counts.</measure>
    <time_frame>At Week 24</time_frame>
    <description>A responder is a subject achieving the following peak eosinophil counts: eosinophil count ≤4 cells per hpf in 5 gastric hpf and/or eosinophil count ≤15 cells per hpf in 3 duodenal hpf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean absolute change in 6 symptom total symptom score (TSS: abdominal pain, nausea, abdominal cramping, loss of appetite, fullness before finishing a meal, and bloating ) as measured by the PRO questionnaire (score from 0 none - 10 worst)</measure>
    <time_frame>Baseline to Weeks 23 - 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in tissue eosinophils</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment responders as defined by &gt;30% improvement in symptoms and mean eosinophil count ≤4 cells/hpf in 5 gastric hpf and/or mean eosinophil count ≤15 cells/hpf in 3 duodenal hpf.</measure>
    <time_frame>Baseline to Weeks 23-24 and at Week 24, respectively.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving mean eosinophil count ≤1 cell/hpf in 5 highest gastric hpf and mean eosinophil count ≤1 cell/hpf in 3 highest duodenal hpf</measure>
    <time_frame>At Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who show ≥50% reduction in TSS</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who show ≥70% reduction in TSS</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly TSS over time</measure>
    <time_frame>Baseline to Weeks 23-24</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Eosinophilic Gastritis</condition>
  <condition>Eosinophilic Duodenitis</condition>
  <arm_group>
    <arm_group_label>SC 150 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of 150 mg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 300 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of 300 mg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 450 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 6 monthly doses of 450 mg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK002</intervention_name>
    <description>Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1) monoclonal antibody directed against Siglec-8</description>
    <arm_group_label>SC 150 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 300 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 450 mg of lirentelimab (AK002)</arm_group_label>
    <other_name>Lirentelimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent.&#xD;
&#xD;
          2. Male or female aged ≥18 and ≤80 years at the time of signing the informed consent for&#xD;
             entry.&#xD;
&#xD;
          3. Baseline endoscopic biopsy with ≥30 eosinophils/hpf in at least 5 hpf in the stomach&#xD;
             and/or ≥30 eosinophils/hpf in at least 3 hpf in the duodenum as determined by central&#xD;
             histology assessment of biopsies collected during the screening EGD without any other&#xD;
             significant cause for the eosinophilia.&#xD;
&#xD;
          4. Completion of at least 4 daily PRO questionnaires per week for a minimum of 3 weeks&#xD;
             during screening.&#xD;
&#xD;
          5. A weekly average score of abdominal pain, nausea, or diarrhea ≥3 on the PRO&#xD;
             questionnaire (score from 0-10) and a weekly average TSS of ≥10 for at least 2 weeks&#xD;
             of screening.&#xD;
&#xD;
          6. Subjects with inadequate or loss of response to, or who were intolerant to standard&#xD;
             therapies for EG and/or EoD, which could include PPI, antihistamines, systemic or&#xD;
             topical corticosteroids, and/or diet, among others.&#xD;
&#xD;
          7. If subject is on preexisting dietary restrictions, willingness to maintain dietary&#xD;
             restrictions throughout the study.&#xD;
&#xD;
          8. Willing and able to comply with all study procedures and visit schedule including&#xD;
             follow-up visits.&#xD;
&#xD;
          9. Female subjects must be either post-menopausal for at least 1 year with FSH level &gt;30&#xD;
             mIU/mL at screening or surgically sterile (tubal ligation, hysterectomy, or bilateral&#xD;
             oophorectomy) for at least 3 months, or if of childbearing potential, have a negative&#xD;
             pregnancy test and agree to use dual methods of contraception, or abstain from sexual&#xD;
             activity from screening until the end of the study, or for 120 days following the last&#xD;
             dose of study drug, whichever is longer. Male subjects with female partners of&#xD;
             childbearing potential must agree to use a highly effective method of contraception&#xD;
             from screening until the end of the study or for 120 days following the last dose of&#xD;
             study drug, whichever is longer. All fertile men with female partners of childbearing&#xD;
             potential should be instructed to contact the Investigator immediately if they suspect&#xD;
             their partner might be pregnant (e.g., missed or late menstrual period) at any time&#xD;
             during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of systemic or topical corticosteroids exceeding the equivalent of 10 mg/day of&#xD;
             prednisone within 4 weeks prior to the screening visit.&#xD;
&#xD;
          2. Change in the dose of corticosteroids (systemic or topical), PPI, leukotrienes, or&#xD;
             diet therapy within 4 weeks prior to the screening visit.&#xD;
&#xD;
          3. Treatment with any immunosuppressive or immunomodulatory drugs that may interfere with&#xD;
             the study within 12 weeks prior to the screening visit.&#xD;
&#xD;
          4. Prior exposure to AK002 or known hypersensitivity to any constituent of the study&#xD;
             drug.&#xD;
&#xD;
          5. Active Heliobacter pylori (H. pylori) infection as confirmed by stool antigen test for&#xD;
             H. pylori or identified in tissue biopsies obtained at screening EGD.&#xD;
&#xD;
          6. History of inflammatory bowel disease, celiac disease, achalasia, or esophageal&#xD;
             surgery.&#xD;
&#xD;
          7. History of bleeding disorders and/or esophageal varices considered to be clinically&#xD;
             significant by the Investigator.&#xD;
&#xD;
          8. Other significant gastric and/or duodenal eosinophilia or eosinophilic granulomatosis&#xD;
             with polyangiitis (EGPA).&#xD;
&#xD;
          9. Confirmed diagnosis of hypereosinophilic syndrome (HES).&#xD;
&#xD;
         10. Women who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the study.&#xD;
&#xD;
         11. Presence of an abnormal laboratory value considered to be clinically significant by&#xD;
             the Investigator.&#xD;
&#xD;
         12. Any disease, condition (medical or surgical), or cardiac abnormality, which, in the&#xD;
             opinion of the Investigator, would place the subject at increased risk.&#xD;
&#xD;
         13. History of malignancy, except carcinoma in situ, early-stage prostate cancer, or&#xD;
             non-melanoma skin cancers. However, subjects with cancers that have been in remission&#xD;
             for more than 5 years and are considered cured can be enrolled.&#xD;
&#xD;
         14. Treatment for a clinically significant helminthic parasitic infection within 6 months&#xD;
             of screening.&#xD;
&#xD;
         15. Positive helminthic infection on Ova and Parasite (O&amp;P) test.&#xD;
&#xD;
         16. Seropositive for Strongyloides stercoralis at screening.&#xD;
&#xD;
         17. Seropositive for HIV or hepatitis at screening except for vaccinated subjects or&#xD;
             subjects with past but resolved hepatitis at screening.&#xD;
&#xD;
         18. Vaccination with live attenuated vaccines within 30 days prior to initiation of&#xD;
             treatment in the study or expected during the treatment period. Vaccines authorized by&#xD;
             FDA or other regulatory authority for the prevention of COVID-19 may be administered&#xD;
             before, during, or after this protocol as per the label. The vaccine should not be&#xD;
             administered within 7 days prior to and within 7 days after the administration of&#xD;
             AK002 so that the side effects caused by either of the 2 medications can be more&#xD;
             easily determined.&#xD;
&#xD;
         19. Participation in a concurrent interventional study with the last intervention&#xD;
             occurring within 30 days prior to study drug administration (or 90 days or 5&#xD;
             half-lives, whichever is longer, for biologic products).&#xD;
&#xD;
         20. Known history of alcohol, drug, or other substance abuse or dependence that is&#xD;
             considered by the Investigator to be ongoing and clinically significant.&#xD;
&#xD;
         21. Any other reason that in the opinion of the Investigator or the Medical Monitor makes&#xD;
             the subject unsuitable for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Paterson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Paterson, MD</last_name>
    <phone>650-597-5002</phone>
    <email>info@allakos.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Connecticut</state>
        <zip>06010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Bay Saint Louis</city>
        <state>Mississippi</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Springboro</city>
        <state>Ohio</state>
        <zip>45066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <zip>44145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Hixson</city>
        <state>Tennessee</state>
        <zip>37343</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84092</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allakos Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophil</keyword>
  <keyword>Eosinophilic</keyword>
  <keyword>Eosinophilic gastrointestinal disorders</keyword>
  <keyword>EGID</keyword>
  <keyword>EG</keyword>
  <keyword>EGE</keyword>
  <keyword>Eosinophilic Gastritis</keyword>
  <keyword>Eosinophilic Duodenitis</keyword>
  <keyword>Eosinophilic Gastroenteritis</keyword>
  <keyword>EoD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
    <mesh_term>Enteritis</mesh_term>
    <mesh_term>Duodenitis</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

